Zhejiang Jiuzhou Pharmaceutical (603456.SH): The application for listing of p-toluenesulfonic acid edaravone chemical raw materials has been approved.
Jiu Zhou Pharmaceutical (603456.SH) announced that the company has received a notice issued by the National Medical Products Administration regarding the approval of methanesulfonic acid...
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that the company has received the "Chemical raw material drug market application approval letter" for the compound benzenesulfonic acid edoxaban from the National Medical Products Administration. Benzenesulfonic acid edoxaban is an oral anticoagulant used primarily to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat or prevent deep vein thrombosis and pulmonary embolism.
Related Articles
MGM China (02282) spent HKD 732,600 to buy back 47,000 shares on November 24th.
BJ ENT URBAN (03718) won two projects in Chengde City, Hebei Province and Nanjing City, Jiangsu Province.
Technology Group (00103) spent HK$61,800 on November 24 to repurchase 19,000 shares.
MGM China (02282) spent HKD 732,600 to buy back 47,000 shares on November 24th.
BJ ENT URBAN (03718) won two projects in Chengde City, Hebei Province and Nanjing City, Jiangsu Province.
Technology Group (00103) spent HK$61,800 on November 24 to repurchase 19,000 shares.
